R. Lincoln Family Foundation. Data collection and sharing for this project selleck screening library was funded by the ADNI (National Institutes of Health Grant U01 “type”:”entrez-nucleotide”,”attrs”:”text”:”AG024904″,”term_id”:”7683568″,”term_text”:”AG024904″AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc.

, as well as non-profit partners, the Alzheimer’s Association and Alzheimer’s Drug Discovery Foundation, with participation from the US Food and Drug Administration. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health [30]. The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuroimaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 “type”:”entrez-nucleotide”,”attrs”:”text”:”AG010129″,”term_id”:”3294405″,”term_text”:”AG010129″AG010129, K01 “type”:”entrez-nucleotide”,”attrs”:”text”:”AG030514″,”term_id”:”16557387″,”term_text”:”AG030514″AG030514, and the Dana Foundation.

Alzheimer’s Disease Neuroimaging Initiative (ADNI): ‘Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Anacetrapib Initiative (ADNI) database [28]. The ADNI was launched in 2003 by the National Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug Administration (FDA), private pharmaceutical companies and non-profit organizations, as a $60 million, 5-year public private partnership. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and the progression of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). Determination of sensitive and specific markers of very early AD progression is intended to aid researchers and clinicians to develop new treatments and monitor selleck kinase inhibitor their effectiveness, as well as lessen the time and cost of clinical trials. The Principal Investigator of this initiative is Michael W Weiner, MD, VA Medical Center and University of California – San Francisco.